Ibuprofen has been the default recovery tool in every gym bag for decades. Pop two after a hard session, move on. But a growing body of research — and a quiet shift in professional locker rooms — suggests that default might be due for an update.
The NSAID Problem Nobody Talks About
Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen are effective at reducing inflammation and pain in the short term. That's not the issue. The issue is what happens when short-term becomes habitual — and for athletes training four, five, six days a week, habitual comes fast.
Prolonged NSAID use carries documented risks to the gastrointestinal tract, kidneys, and cardiovascular system. The National Kidney Foundation has flagged repeated NSAID use as a contributor to kidney damage. The FDA itself has strengthened warnings about heart attack and stroke risk with long-term use. Ultradistance athletes are typically advised to avoid NSAIDs entirely during events due to heightened renal risk.
And here's the part that should matter most to anyone who trains seriously: NSAIDs may actually impair the adaptations you're training for. A narrative review published in Sports Medicine noted that blocking inflammation with ibuprofen could attenuate exercise-induced skeletal muscle adaptation — potentially limiting angiogenesis and hypertrophy. In other words, the thing you're taking to recover faster might be slowing down the recovery it's supposed to support.
How CBD Topicals Work Differently
CBD (cannabidiol) interacts with the body's endocannabinoid system (ECS), a network of receptors that modulates pain, inflammation, and immune response. Unlike NSAIDs, which work by inhibiting COX enzymes systemically, a CBD topical applied to the skin engages cannabinoid receptors locally — in the skin and underlying tissue — without entering the bloodstream in meaningful concentrations.
This distinction matters for two reasons. First, topical application avoids the GI, renal, and cardiovascular risks associated with oral NSAIDs because the compound stays localized. Second, CBD's anti-inflammatory mechanism doesn't appear to block the beneficial inflammatory signaling that drives muscle repair and adaptation.
NSAIDs suppress inflammation by blocking COX enzymes — the same enzymes involved in tissue healing. CBD modulates the inflammatory response through the endocannabinoid system without fully suppressing it. For athletes, this difference between suppression and modulation is significant.
The Side-by-Side
| Factor | Ibuprofen (Oral NSAID) | CBD Topical Balm |
|---|---|---|
| Mechanism | COX enzyme inhibition (systemic) | ECS receptor modulation (local) |
| Delivery | Oral — enters bloodstream | Topical — stays localized |
| GI Risk | Ulcers, bleeding, "leaky gut" during endurance events | None — bypasses GI tract entirely |
| Kidney Risk | Documented with chronic use | None — topical doesn't reach kidneys |
| Cardiovascular | FDA-warned increased risk with long-term use | No documented cardiovascular risk |
| Muscle Adaptation | May impair hypertrophy and angiogenesis | No evidence of impaired adaptation |
| WADA Status | Permitted | CBD removed from prohibited list in 2018 |
| Onset | ~30 minutes | Minutes (topical, localized) |
What the Research Actually Says
It's worth being direct here: the evidence base for CBD in athletic recovery is still early. Most existing studies are preclinical or involve small sample sizes, and the research that does exist tends to focus on oral CBD rather than topicals specifically.
That said, the trajectory is clear. A 2020 review in Frontiers in Pharmacology found evidence that CBD can reduce inflammation in muscles and support recovery time. A study in the Journal of Pain Research reported that 62% of CBD users experienced meaningful reductions in pain. A 2025 Sports Medicine study noted modest but significant reductions in inflammation, while calling for more athlete-specific trials.
On the other side, a double-blind randomized controlled trial found that topical CBD ointment didn't meaningfully improve delayed-onset muscle soreness (DOMS) at 24, 48, or 72 hours post-exercise. And a 2024 University of Bath study raised questions about CBD's efficacy for chronic pain specifically.
This isn't a slam dunk in either direction. What it is: a growing signal that CBD — particularly in topical form — offers a different risk-benefit profile than the NSAIDs athletes have defaulted to for decades. The safety advantages are clearer than the efficacy advantages at this stage. That matters if you're someone who applies something to your body every day.
The Concentration Variable
Not all CBD topicals are equivalent, and concentration is the variable most consumers overlook. Many mass-market CBD balms contain 250–500mg of CBD per container. At that concentration, a single application delivers a negligible amount of cannabinoid to the tissue.
Research and athlete protocols that show results tend to involve higher concentrations. A topical with 3,000mg of CBD in a 30ml jar delivers 100mg per milliliter — meaning each application puts a meaningful dose in contact with the target area. A topical with 250mg in the same size jar delivers roughly 8mg per ml. That's a 12x difference in concentration per application.
When evaluating any CBD topical, divide total mg by total ml. That gives you concentration per application. Most products on the market fall between 5–20mg/ml. Research-grade and professional-use products tend to start at 50mg/ml and go up. If the label doesn't make this calculation easy, ask why. Learn more about concentration →
What Athletes Are Actually Doing
The shift is happening in practice regardless of where the research settles. The World Anti-Doping Agency removed CBD from its prohibited substances list in 2018. Since then, cannabinoids have risen to the second most-used substance among contact sports athletes. Surveys of endurance athletes show that roughly one-third of cyclists, triathletes, and runners have tried cannabinoids at some point, with 93% of those users reporting that CBD aided their recovery.
Professional athletes across sports — from MMA to soccer to ultrarunning — have publicly adopted CBD topicals as part of their recovery protocols, frequently citing reduced reliance on over-the-counter pain relievers as a primary motivation.
The pattern isn't "CBD replaces everything." It's "CBD topicals handle the daily localized soreness that used to mean reaching for ibuprofen three or four times a week." NSAIDs still have a role for acute injury and acute inflammation. The question is whether they should be the default daily recovery tool — and increasingly, the answer from athletes and researchers alike is no.
What to Look for in a CBD Topical
Third-party lab testing. Any legitimate CBD topical will have a Certificate of Analysis (COA) from an independent lab. This verifies cannabinoid concentration, confirms THC content is below 0.3%, and screens for contaminants like heavy metals, pesticides, and residual solvents. If a brand doesn't publish their COA, that tells you everything you need to know. How to read a COA →
Full-spectrum vs. isolate. Full-spectrum hemp extract contains CBD along with other naturally occurring cannabinoids, terpenes, and flavonoids. Research suggests these compounds work synergistically — often called the "entourage effect" — producing a more complete interaction with the endocannabinoid system than CBD isolate alone. For topical use specifically, this broader cannabinoid profile means more receptor engagement at the application site.
Concentration (mg/ml). Already covered above, but it's the single most important number on any CBD topical. Don't compare total mg across different container sizes. Compare mg per ml.
Carrier and base ingredients. The base formula affects absorption. Look for carriers like MCT oil or shea butter that support transdermal delivery. Avoid products loaded with fillers, artificial fragrances, or long ingredient lists that suggest the CBD is an afterthought.
Metric Recovery Balm: 3,000mg full-spectrum CBD · 100mg/ml concentration · 5 organic ingredients · USDA organic hemp · Third-party tested by MCR Labs · View COA →
Sources
1. McCartney, D., et al. "Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research." Sports Medicine - Open, 2020.
2. National Kidney Foundation. "Painkillers and the Kidneys." kidney.org.
3. U.S. Food and Drug Administration. "FDA Drug Safety Communication: FDA strengthens warning that non-aspirin NSAIDs can cause heart attacks or strokes." fda.gov, 2015 (updated).
4. "Cannabidiol (CBD) — what we know and what we don't." Harvard Health Publishing, 2024.
5. Frontiers in Pharmacology. "Anti-inflammatory Properties of Cannabidiol." 2020.
6. World Anti-Doping Agency. "Summary of Major Modifications and Explanatory Notes: 2018 Prohibited List." wada-ama.org.
7. Cochrane Database of Systematic Reviews. "Topical NSAIDs for acute musculoskeletal pain in adults." Updated 2015.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Statements about CBD have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before making changes to your recovery or pain management routine.